Zhang Weihan, Chen Xinzu, Liu Kai, Yang Kun, Chen Xiaolong, Zhao Ying, Zhao Yongfan, Chen Jiaping, Chen Longqi, Hu Jiankun
Department of Gastrointestinal Surgery; Institute of Gastric Cancer, State Key Laboratory of Biotherapy.
Department of Gastrointestinal Surgery; Department of Discipline Construction.
Chin J Cancer Res. 2016 Aug;28(4):413-22. doi: 10.21147/j.issn.1000-9604.2016.04.04.
To compare the survival outcomes of transabdominal (TA) and transthoracic (TT) surgical approaches in patients with Siewert-II/III esophagogastric junction adenocarcinoma.
This retrospective study was conducted in patients with Siewert-II/III esophagogastric junction adenocarcinoma who underwent either TT or TA operations in the West China Hospital between January 2006 and December 2009.
A total of 308 patients (109 in the TT and 199 in the TA groups) were included in this study with a follow-up rate of 87.3%. The median (P25, P75) number of harvested perigastric lymph nodes was 8 (5, 10) in the TT group and 23 (16, 34) in the TA group (P<0.001), and the number of positive perigastric lymph nodes was 2 (0, 5) in the TT group and 3 (1, 8) in the TA group (P<0.004). The 5-year overall survival (OS) rate was 36% in the TT group and 51% in the TA group (P=0.005). Subgroup analysis by Siewert classification showed that 5-year OS rates for patients with Siewert II tumors were 38% and 48% in TT and TA groups, respectively (P=0.134), whereas the 5-year OS rate for patients with Siewert III tumors was significantly lower in the TT group than that in the TA group (33% vs. 53%; P=0.010). Multivariate analysis indicated that N2 and N3 stages, R1/R2 resection and a TT surgical approach were prognostic factors for poor OS.
Improved perigastric lymph node dissection may be the main reason for better survival outcomes observed with a TA gastrectomy approach than with TT gastrectomy for Siewert III tumor patients.
比较经腹(TA)和经胸(TT)手术方式治疗Siewert-II/III型食管胃交界腺癌患者的生存结局。
本回顾性研究纳入了2006年1月至2009年12月期间在华西医院接受TT或TA手术的Siewert-II/III型食管胃交界腺癌患者。
本研究共纳入308例患者(TT组109例,TA组199例),随访率为87.3%。TT组胃周淋巴结清扫中位数(P25,P75)为8枚(5,10),TA组为23枚(16,34)(P<0.001);TT组胃周阳性淋巴结数为2枚(0,5),TA组为3枚(1,8)(P<0.004)。TT组5年总生存率(OS)为36%,TA组为51%(P=0.005)。按Siewert分型进行亚组分析显示,Siewert II型肿瘤患者TT组和TA组的5年OS率分别为38%和48%(P=0.134),而Siewert III型肿瘤患者TT组的5年OS率显著低于TA组(33%对53%;P=0.010)。多因素分析表明,N2和N3期、R1/R2切除以及TT手术方式是OS不良的预后因素。
对于Siewert III型肿瘤患者,TA胃切除术比TT胃切除术观察到更好的生存结局,可能主要原因是胃周淋巴结清扫的改善。